Cereno Scientific strives to disrupt cardiovascular treatments worldwide by unlocking the potential of epigenetic modulation...
Location: Sweden, Mölndal
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Mentions in press and media 10
| Date | Title | Description |
| 30.11.2025 | Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 Sun, Nov 30, 2025 10:17 CET Report this content Correction: In the press release published on November 28, ... |
| 28.11.2025 | Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 Fri, Nov 28, 2025 19:30 CET Report this content THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRE... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! Mon, May 29, 2023 09:45 CET Report this content It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 09.02.2022 | Cereno Scientific publishes year-end report for 2021 (1 January – 31 December) | Cereno Scientific publishes year-end report for 2021 (1 January – 31 December) Wed, Feb 09, 2022 08:15 CET Report this content The Board and Chief Executive Officer of Cereno Scientific AB here presents the year-end report for the year 2021... |
| 16.11.2021 | Cereno Scientific publishes interim report for Q3 2021 | Cereno Scientific publishes interim report for Q3 2021 Tue, Nov 16, 2021 08:31 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for Q3, 1 July – 30 September, 2021. Summary of the third quar... |
| 05.10.2021 | BioStock: Cereno Scientific raises 95.3 million SEK | BioStock: Cereno Scientific raises 95.3 million SEK Tue, Oct 05, 2021 08:56 CET The recent IND FDA acceptance to initiate its phase II trial with CS1 in pulmonary arterial hypertension patients was a key milestone for Cereno Scientific. Las... |
| 01.10.2021 | Warrants of series TO1 were subscribed to approximately 96.9 percent and Cereno Scientific AB (publ) receives approximately SEK 95.3 million. | Warrants of series TO1 were subscribed to approximately 96.9 percent and Cereno Scientific AB (publ) receives approximately SEK 95.3 million. Fri, Oct 01, 2021 08:15 CET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRE... |
| 25.08.2021 | Cereno Scientific publishes interim report for Q2 2021 | Cereno Scientific publishes interim report for Q2 2021 Wed, Aug 25, 2021 15:30 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for Q2, 1 April – 30 June, 2021. Summary of the second quarter... |
| 09.06.2021 | Press release from Annual General Meeting of Cereno Scientific AB | Press release from Annual General Meeting of Cereno Scientific AB Wed, Jun 09, 2021 10:50 CET The Annual General Meeting of Cereno Scientific AB (“Cereno”) was held today 9 June 2021. Due to the ongoing Covid-19 pandemic, the annual general... |
| 19.05.2021 | Cereno Scientific publishes interim report Q1 2021 | Cereno Scientific publishes interim report Q1 2021 Wed, May 19, 2021 08:30 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for Q1, 1 January – 31 March, 2021. Summary of the first quarter, ... |